Futibatinib is a targeted therapy medication that works by blocking specific proteins that contribute to cancer growth. It belongs to a class of drugs known as FGFR inhibitors, which can help stop the spread of certain types of cancer cells.

Tislelizumab is an immunotherapy medication that helps the body’s immune system fight cancer cells. It works by blocking a protein called PD-1, which normally prevents the immune system from attacking cancer cells. By blocking PD-1, tislelizumab allows the immune system to better recognize and destroy cancer cells.

Chemotherapy (specific agents not mentioned in the source data) is a traditional cancer treatment that uses drugs to kill rapidly dividing cells, including cancer cells. It may be given in combination with the other medications to provide a comprehensive treatment approach.

Colorectal cancer – A disease that begins when cells in the colon or rectum start growing out of control. It typically starts as small growths called polyps on the inner lining of the colon or rectum. Over time, some of these polyps can develop into cancer, growing into the wall of the colon or rectum. The disease usually develops slowly over several years. As the cancer grows, it can spread through the layers of the colon or rectal wall and eventually to other parts of the body. Early stages of the disease may not cause noticeable symptoms.